1. Bioinformatics and Systems Biology: Application of bioinformatics and systems biology tools for “omics” data integration to identify markers related to diabetes and related characteristics.
2. Metabolomics and patient stratification: Use of metabolomics and lipidomics in combination with clinical data for patient stratification with the aim for clinical applications in diabetes.
1. RHAPSODY ( Assessing risk and progression of pre-diabetes and type 2 diabetes to enable disease modification)
The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.
Aim: The overall objective of INNODIA therefore is to advance in a decisive way how we predict, evaluate and prevent the onset and progression of type 1 diabetes (T1D), by creating novel tools, such as biomarkers, disease models and clinical trial paradigms. These tools will allow to distinguish and understand at the cellular and molecular level distinctive paths of ontogeny and progression in this heterogeneous disease, thus impacting on the future management of T1D patients and at risk individuals.